<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085824</url>
  </required_header>
  <id_info>
    <org_study_id>CPX-2012</org_study_id>
    <nct_id>NCT02085824</nct_id>
  </id_info>
  <brief_title>Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.</brief_title>
  <official_title>Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre of Postgraduate Medical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre of Postgraduate Medical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which of the following drugs: enoxaparin,
      dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total blood loss by the 3rd postoperative day</measure>
    <time_frame>3rd day postoperatively</time_frame>
    <description>Measured for each individual. Measured according to the formula described by Nadler, Hidalgo and Bloch (Prediction of blood volume in normal human adults. Surgery 1962;51:224-32).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drop in the haemoglobin value between 3rd day postop and preoperative</measure>
    <time_frame>3rd day postopertively</time_frame>
    <description>Difference between haemoglobin on the 3rd postopertive day and day before operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing disturbances according to the definition of Centers for Disease Control and Prevention</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>Wound healing disturbances - diagnosis to be made according to the definition of Centers for Disease Control and Prevention (Mangram, Horan, Pearson, Silver and Jarvis. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <arm_group_label>rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <arm_group_label>dabigatran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary, end-stage hip osteoarthritis requiring total hip arthroplasty

        Exclusion Criteria:

          -  inflammatory arthropathies

          -  liver disorders

          -  neoplastic conditions

          -  clotting disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcin K Wasko, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Medical Centre of Postgraduate Education, Department of Orthopaedics and Inflammatory Disorders of Locomotor System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcin K Wasko, M.D., Ph.D.</last_name>
    <phone>+48227794031</phone>
    <phone_ext>384</phone_ext>
    <email>m.wasko@cmkp.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education</name>
      <address>
        <city>Otwock</city>
        <state>Woj. Mazowieckie</state>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marcin K Wasko, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre of Postgraduate Medical Education</investigator_affiliation>
    <investigator_full_name>Marcin Wasko MD PhD</investigator_full_name>
    <investigator_title>Dr Marcin Wasko MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

